• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.640 -0.390 (-6.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,744,520
Open 6.030
Bid (Size) 5.660 (200)
Ask (Size) 6.100 (100)
Prev. Close 6.030
Today's Range 5.565 - 6.030
52wk Range 1.890 - 7.005
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's pre-market session ↗
January 02, 2026
Via Chartmill
News headline image
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
December 22, 2025
From Savara Inc.
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
-13.2%
-13.2%
3 Month
+63.0%
+63.0%
6 Month
+141.0%
+141.0%
1 Year
+84.9%
+84.9%

More News

Read More
News headline image
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
December 11, 2025
From Savara Inc.
Via Business Wire
News headline image
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
December 02, 2025
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
November 20, 2025
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From Savara Inc.
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
November 10, 2025
From Schall Law
Via GlobeNewswire
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
November 07, 2025
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
November 07, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
November 06, 2025
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
November 06, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
November 06, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
November 06, 2025
From Schall Law
Via GlobeNewswire
News headline image
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRA
November 06, 2025
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRA
November 06, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRA
November 05, 2025
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRA
November 05, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
November 04, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Lost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
November 04, 2025
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Lost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
November 04, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
November 04, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
November 03, 2025
From Savara Inc.
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
November 03, 2025
From Schall Law
Via GlobeNewswire
News headline image
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
October 31, 2025
From Savara Inc.
Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 5.640
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 643.33M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 643M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap